Correlation Between Spyre Therapeutics and Volaris

Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and Volaris at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and Volaris into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Spyre Therapeutics and Volaris, you can compare the effects of market volatilities on Spyre Therapeutics and Volaris and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of Volaris. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and Volaris.

Diversification Opportunities for Spyre Therapeutics and Volaris

-0.37

Correlation Coefficient

Spyre Therapeutics  Volaris

Very good diversification

The 3 months correlation between Spyre and Volaris is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and Volaris in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Volaris and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with Volaris. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Volaris has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and Volaris go up and down completely randomly.

Pair Corralation between Spyre Therapeutics and Volaris

Given the investment horizon of 90 days Spyre Therapeutics is expected to under-perform the Volaris. In addition to that, Spyre Therapeutics is 1.96 times more volatile than Volaris. It trades about -0.12 of its total potential returns per unit of risk. Volaris is currently generating about -0.11 per unit of volatility. If you would invest  841.00  in Volaris on October 15, 2024 and sell it today you would lose (29.00) from holding Volaris or give up 3.45% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Spyre Therapeutics  vs.  Volaris

Spyre Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Volaris

Risk-Adjusted Performance

13 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Volaris are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Volaris unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Spyre Therapeutics and Volaris

The main advantage of trading using opposite Spyre Therapeutics and Volaris positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, Volaris can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Volaris will offset losses from the drop in Volaris' long position.

The idea behind Spyre Therapeutics and Volaris pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.